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The study aims to prepare naproxen enteric-coated pellets (NAP-ECPs) by fluid-bed coating
using QbD principle. Risk assessment was firstly performed by using failure mode and
effect analysis (FMEA) methodology. A PlacketteBurman design was then used for
assessment of the most important variables affecting enteric-coated pellets characteris-
tics. A BoxeBehnken design was subsequently used for investigating the main, interactive,
and quadratic effects of these variables on the response. By FMEA we discovered that eight
factors should be considered to be high/important risk variables as compared with others.
The responses of acid resistance and cumulative drug release were taken as critical quality
attributes (CQAs). Pareto ranking analyses indicated that the coating weight gain (X7),
triethyl citrate percentage (X1) and glycerol monostearate percentage (X2) were the most
significant factors affecting the selected responses out of the eight high-risk variables.
Optimization with response surface method (RSM) further fully clarified the relationship
between X7, X1, X2 and CQAs, and design space was established based on the constraints
set on the responses. Due to the extreme coincidence of the predicted value generated by
model with the observed value, the accuracy and robustness of the model were confirmed.
It could be concluded that a promising NAP-ECPs was successfully designed using QbD
approach in a laboratory scale.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Pharmaceutical development involves traditional and sys-
tematic approaches. The former mainly depends on empiricaland Microparticle Drug D
(J. Liu).
g Pharmaceutical Univer
University. Production anevaluation of product and process performance, which pays
little attention to the impact of multivariable on formulation
and the process understanding. Product quality is identified
mainly by restricting flexibility in the manufacturing process
and end product testing (so called quality-by-testing, QbT) [1].elivery Systems, No. 24, Tong Jia Xiang, Nanjing 210009, China.
sity.
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pharmaceutical development. The latter is pharmaceutical
Quality by design (QbD) philosophy, which is amore scientific,
risk-based, holistic and proactive approach with proper feed-
forward and feed-back control strategies to pharmaceutical
development. The approach builds quality into product during
the pharmaceutical development but not merely testing for it
[2], which helps to thoroughly understand the root-cause,
such as critical material attributes and process parameters
that impacting the predefined quality attributes [3]. The
following equation clearly illustrates what affects the product
quality: Pharmaceutical Quality ¼ F (drug substance, excipi-
ents, manufacturing, packaging, et al). The function F in the
equation contributes to understand how the formulation
variables and process parameters influence the end product
profile [3], hence developing accurate and robust product.
Building from the QbD paradigm, methods can be used up-
stream at the beginning stages of the research, development
and design phases [4], meanwhile the product quality should
be proactively controlled in the manufacturing process. By
developing a product with QbD principles, end product testing
would be only used for the confirmation of product quality [1].
QbD is concerned with the certain predictable quality
through linking the critical material attributes (CMAs) and
critical process parameters (CPPs) into the critical quality at-
tributes (CQAs) of drug product. The application of QbD
concept in pharmaceutical development is presented graphi-
cally in Fig. 1. Firstly, the potential risk factors are determined
by risk assessment in the initial design during product
development. Then, to improve process knowledge, multi-
variate experiments are carried out using design of experi-
ments (DOE). DOE method can link the inputs to the outputs,Fig. 1 e QbD, risk management and quality mas such, the relationships between CPPs and CQAs are well
understood inmathematical form and the design space (DS) is
further established [5]. The most common used of DOE is
PlacketteBurman, which can quickly screen the main factors
among numerous inputs variables [6]. However, the disad-
vantage of PlacketteBurman design is that interactions be-
tween variables are generally confounded and cannot be
easily determined, as there are not enough degrees of
freedom. BoxeBehnken design were usually used to establish
DS for it can determine the variables range which requires
fewer runs than a central composite design [7].
Solid dosage form owns amajority share in themarket and
pellets are achieving increasing attention as multiple units
preparations for possessing remarkable advantages, including
less effect by gastric emptying rhythm, homogeneous distri-
bution in gastrointestinal (GI) tract thus maximizing drug
absorption, reducing the risk of local GI tract irritation [8,9].
Film coating processes are widely used due to its outstanding
functions in oral solid drug delivery system, such as masking
unpleasant taste, improving stability, enhancing appearance,
adding an active compound and controlling release rate [10].
Based on the above, the coating pellets dosage form is
compelling and desirable, besides, and the fluid-bed tech-
nique is a valuable approach to obtain coating pellets. Enteric-
coating is the most common method for manufacturing oral
solid preparation especially when the drug acid stability/
dissolution or irritation to gastric mucosa is an issue. The
coating pellets process consists of two phases: firstly, the
pellets core containing drug should be obtained, and then the
pellets are coated with enteric-coating materials. To date, the
application of QbD for pharmaceutical development of
enteric-coated pellets has yet been reported. Naproxen (NAP),anagement in formulation development.
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of which has a positive association of pH, meanwhile along
with local gastric irritation, is used as a model compound to
develop Naproxen enteric-coated pellets (NAP-ECPs). In pre-
vious work, we had successfully prepared NAP-loaded im-
mediate-release pellets (NAP-IRPs) starter cores by extrusion-
spheronization by using QbD concept (the related contents are
to be published).
The ultimate purpose of our study is to comprehensively
link the CQAs, variables among DOE batches, to upstream
manufacturing process and material attributes so as to iden-
tify factors affecting the CQAs. The elements in QbD are
fourfold: (1) a risk assessment was performed to identify the
main variables influencing the selected quality attributes of
NAP-ECPs; (2) a PlacketteBurman screening design was used
to determine the most significant factors affecting formula-
tion composition and process parameters on acid resistance
(Y1) and cumulative drug release (Y2); (3) a BoxeBehnken
optimization design was applied in the response surface
method (RSM) study to obtain the exact relationship between
the preparation CQAs and various factors. DS was established
following the obtained response surface, control space (CS)
was further achieved. (4) moreover, verification experiments
were carried out to identify the robustness and accuracy of the
generated model.2. Material and methods
2.1. Material
Naproxen (Volume average particle diameter of 32.822 mm)
was purchased from Zhejiang Charioteer Pharmaceutical Co.
Ltd. (Taizhou, China). Naproxen standardwas purchased from
National Institutes for Food and Drug Control (Beijing, China).
Microcrystalline cellulose (MCC, Avicel® PH 101) and Cro-
scarmellose Sodium (CCMC-Na, Ac-Di-Sol®SD-711NF) were
kindly donated from FMC Biopolymer (Newark, U.S.A.).
Lactose Monohydrate (GranuLac®200) and Poly-
vinylpyrrolidone (PVP K29-32) were gifts from Meggle GmbH
(Wasserburg, Germany) and by China Division, ISP Chemicals
Co. Ltd (Shanghai, China), respectively. Tween-80 was the
product of Sinopharm Chemical Reagent Co. Ltd (Shanghai,
China). Triethyl citrate were purchased from Aladdin Chem-
istry Co. Ltd (Shanghai, China). Glycerol monostearate were
purchased from Nanjing Chemical Reagent Co. Ltd (Nanjing,
China). Eudragit L30D-55 was kindly provided by Evonik In-
dustries (Darmstadt, Germany). Hydrochloric acid was pur-
chased from Nanjing Chemical Reagent Co. Ltd (Nanjing,
China). Sodium phosphate dibasic were purchased from
Shanghai Ling Feng Chemical Reagent Co. Ltd (Shanghai,
China). Sodium dodecyl sulfate were purchased from Nanjing
Chemical Reagent Co. Ltd (Nanjing, China).
2.2. Experimental methods
2.2.1. Preparation of NAP-IRPs starter cores
NAP-IRPs starter cores were prepared by extrusion-
spheronization method. Briefly, NAP, MCC, PVP, Gran-
uLac®200, CCMC-Na and Tween-80 were uniformly mixed atthe weight ratio of 17.00: 9.00: 1.80: 5.78: 1.19: 0.17. Distilled
water was then added in a slow manner and mixed until a
homogeneous and cohesive wet mass was obtained. The wet
mass was then extruded and spheronized in an extrusion-
spheronization apparatus (JBZ-300 multifunctional pelleting
and coating machine, YILIAN new-drug research institute,
China). The resulting pellets were dried in hot air oven at 40 C
for 24 h, afterwards screened through 24e30 meshes.
2.2.2. Preparation of NAP-ECPs
Adding Tween-80 and TEC to the 40% of the total amount
deionized water which is preheated to 80 C and the
mixture was dispersed 2 min at 6000 rpm by homogenizer
(XHF-D high-speed homogenizer, Ningbo Scientz Biotech-
nology Co. Ltd, China). Then GMS was added and being
dispersed 8 min at 6000 rpm under 80 C water bath,
following by adding the residual water and continuously
stirred to the ambient temperature. Thereafter, the above
suspended liquid was added to Eudragit L30D-55 aqueous
dispersion slowly, stirring at middle rate for 1 h. Prior to the
film coating procedure, the blend aqueous dispersion was
sieved with a 60 meshes. Deposition of enteric materials on
the NAP-IRPs starter cores was performed in a fluid-bed
granulator and coater (JHQ-100, Shenyang, China). And
next coating aqueous dispersion was bottom-sprayed onto
NAP-IRPs starter cores from a 1.0 mm diameter nozzle
attached to a peristaltic pump (HL-2, Shanghai, China)
under the condition of 31e32 C coating temperature,
100e150 ml min1 air flow rate, besides, the various spray
rate and atomizing pressure by reference to PlacketteBur-
man design. The coating weight gain was calculated using
the following equation F ¼ (Wb Wa)/Wa  100%. In which,
Wa and Wb are the pellets weight before and after coating
respectively. The content of coating pellets was 47.92%.
NAP-ECPs containing 250 mg of NAP were sealed in hard
gelatin capsules with a manual capsule filling machine
(CapsulCN, Zhejiang, China).
2.2.3. Determination of NAP
Concentrations of NAP in dissolutionmediumwere quantified
by UVevisible spectroscopy (spectrophotometer WFZ UV-
2000, Nanjing, China) at wavelengths of 331 nm. The line-
arity of the method was studied in the range of the drug
concentration 2.0e120.0 mg/ml (r ¼ 0.9997). The RSD of the
intraday and interday precision for NAPwere less than 2%.The
recovery rates for NAP were in the range of 98e102%, and the
RSD were below 2%.
2.2.4. In vitro dissolution study of the NAP-ECPs
Dissolution studies were carried out according to USP 34 XXIII,
apparatus II paddle method at a rotation speed of 50 rpm and
the temperature was maintained at 37 ± 0.5 C. In brief, the
total duration of dissolution was 2 h and 45 min. During the
first 2 h, the preparations were subjected to simulated gastric
media [0.1 M HCl solution containing 0.5% sodium lauryl sul-
fate (SLS)] and during the later 45 min, the preparations un-
derwent simulated intestinalmedia (Buffer pH 6.8). Acid stage:
the dissolution medium was 300 mL of 0.1 M HCl solution
containing 0.5% SLS. Each NAP-ECPs capsule containing
250 mg NAP was put into each vessel. After 2 h, 5 mL of the
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same amount of fresh dissolution medium. The samples were
filtered through 0.45 mm filter and analyzed by UV spectro-
photometer at 331 nm. Buffer stage: After 2 h operation in the
acid stage, 600 ml of 0.1 M K2HPO4 preheated to 37 C was
immediately added into the previous fluid. If necessary, adjust
by 1 M HCl or 1 M NaOH to a pH of 6.8 ± 0.05 (PBS 6.8). The
operationwas continued for 45min. At the end of 45min, 5mL
of the dissolution sample was withdrawn and passed through
0.45 mm filter and analyzed by UVevisible method for NAP as
described above.
2.2.5. Risk assessment
Fish-bone diagram was constructed to identify the potential
risks and corresponding causes. Specifically, acid resistance
and cumulative drug release were identified as the two CQAs.
Based on previous knowledge and initial experimental data,
failure mode and effect analysis (FMEA) method were further
applied in the risk analysis of the parameters of the pellets
coating. Each variable (potential failure mode) was scored in
terms of severity (S), detectability (D) and probability (P). More
broadly, Severity is a measure of the possible consequences of
a failure mode affecting on the safety and efficacy of the final
product. Detectability defined that a failure mode can be
detected. The final parameter probability is considered as the
occurrence probability or the likelihood of a failure. For each
risk, S, D, P scores were multiplied together to produce a “Risk
Priority Number” (RPN), RPN¼ S D P, which represents the
overall magnitude of the risk. We ranked S, D and P of 5 as
worst-case, 1 as best-case value and 3 asmoderate-case value,
and then amaximum RPN of 125 and a minimum RPN of 1 are
possible.
The RPN threshold was set at 60, and any formulation
variable or process parameter with an RPN 60 or above was
regarded as a potential critical factor, that is, potential risks
are evaluated by subsequent process characterization
studies since it possibly has a potential impact on CQAs
and in consequence on product safety and efficacy, while
factors with a lower RPN can be eliminated from further
study [11].Table 1 e PlacketteBurman screening Design of Experiments an
spray rate; X4: atomizing pressure; X5: batch size; X6: coating aq
curing time. The response acid resistance (Y1) and drug cumul
ID Pattern X1 (%) X2 (%) X3 (ml/min) X4 (MPa)
PB-1 þþþþ 16 3 0.25 0.02
PB-2 þþþþ 16 10 0.15 0.04
PB-3 þþþ 10 10 0.25 0.02
PB-4 þþþþ 16 3 0.25 0.04
PB-5 þþþþþ 16 10 0.15 0.04
PB-6 þþþþþþ 16 10 0.25 0.02
PB-7 þþþþþ 10 10 0.25 0.04
PB-8 þþþþþ 10 3 0.25 0.04
PB-9 þþþþ 10 3 0.15 0.04
PB-10 þþþþ 16 3 0.15 0.02
PB-11 þþþþ 10 10 0.15 0.02
PB-12  10 3 0.15 0.02
þhigh level, low level.2.2.6. PlacketteBurman design screening study
Based on the risk assessment results, PlacketteBurman study
was used to screen significant factors influencing selected
CQAs. The coating aqueous dispersion always contained
Tween-80 as emulsifier which was 40% of the GMS amount.
The PlacketteBurman design screening studywith each factor
evaluated at low (1) and high (þ1) levels were summarized in
Table 1. The determination of the low and high values was
derived from the preliminary study results. The responses
evaluated were Y1 and Y2.
2.2.7. BoxeBehnken design optimization study
Relied on the results of the PlacketteBurman screening study,
RSM were applied in order to rapidly achieve the optimal
NAP-ECPs with Design Expert software (Version 8.0.6).
BoxeBehnken design was specifically selected here for afore-
mentioned reasons of requiring fewer runs than a central
composite design [7]. The DOE details were listed in Table 2.
The relationship between the material attributes/process
parameters and CQAs was delineated in the DS. DS was
determined from the common region of successful operating
ranges for multiple CQAs (Table 2). The successful operating
ranges for the Y1, Y2, were determined Y1  10% and Y2  80%,
respectively. Based on the prior knowledge space, the CS was
also determined. It is expected that operation within the CS
will result in a product possessing the desired CQAs.
2.2.8. Confirmation tests of model
To verify the accuracy and robustness of the model, three
different combinations were got at low,medium or high levels
of the selected factors within CS. Formulations at those
compositions were analyzed and further compared the
observed responses with the predicted.
2.2.9. Statistical analyses
The results of PlacketteBurman study were analyzed via the
statistical software of Minitab (version 16.1.0), the influence of
each parameter on the responses was demonstrated in the
constructed Pareto charts, in which the length of each bar
stood for the magnitude of the impact on the response.d their results. X1: TEC percentage; X2: GMS percentage; X3:
ueous dispersion solid content; X7: coatingweight gain; X8:
ative release (Y2) were reported as mean ± SD.
X5 (g) X6 (%) X7 (%) X8 (min) Y1 (%) Y2 (%)
5 15 60 120 8.78 ± 0.14 75.20 ± 1.02
5 15 20 120 12.30 ± 0.32 86.60 ± 1.80
8 15 20 15 11.93 ± 0.28 83.16 ± 1.23
5 25 20 15 12.14 ± 0.22 85.54 ± 1.45
8 15 60 15 9.07 ± 0.20 79.04 ± 1.66
8 25 20 120 12.47 ± 0.19 90.11 ± 1.57
5 25 60 15 6.79 ± 0.33 78.34 ± 1.48
8 15 60 120 3.37 ± 0.25 72.47 ± 0.97
8 25 20 120 6.42 ± 0.24 80.95 ± 1.15
8 25 60 15 5.44 ± 0.22 78.18 ± 1.61
5 25 60 120 7.08 ± 0.47 79.10 ± 1.48
5 15 20 15 7.43 ± 0.25 83.57 ± 1.27
Table 2 e BoxeBehnken optimization Design of Experiments and their results. Acid resistance (Y1) and Drug cumulative
release (Y2) were reported as mean ± SD.
ID Pattern Coating weight gain (%) TEC (%) GMS (%) Y1 (%) Y2 (%)
X7 X1 X2 Y1 Y2
BB-1 þ0 60.00 10.00 6.50 4.51 ± 0.20 56.17 ± 1.47
BB-2 0þ 37.50 16.00 3.00 8.29 ± 0.35 89.04 ± 1.49
BB-3 0þ 37.50 10.00 10.00 7.59 ± 0.31 79.87 ± 1.30
BB-4 000 37.50 13.00 6.50 8.05 ± 0.25 82.76 ± 1.15
BB-5 þþ0 60.00 16.00 6.50 6.47 ± 0.20 70.22 ± 1.21
BB-6 0þþ 37.50 16.00 10.00 10.03 ± 0.28 93.37 ± 1.32
BB-7 0 15.00 10.00 6.50 11.46 ± 0.22 95.12 ± 1.30
BB-8 þ0 15.00 16.00 6.50 13.12 ± 0.31 100.13 ± 0.82
BB-9 0 15.00 13.00 3.00 12.33 ± 0.26 97.33 ± 1.31
BB-10 0þ 15.00 13.00 10.00 12.63 ± 0.28 98.14 ± 1.10
BB-11 þ0þ 60.00 13.00 10.00 6.32 ± 0.18 65.52 ± 1.35
BB-12 0 37.50 10.00 3.00 6.85 ± 0.23 75.46 ± 1.26
BB-13 000 37.50 13.00 6.50 8.14 ± 0.21 84.21 ± 1.33
BB-14 000 37.50 13.00 6.50 7.76 ± 0.23 83.14 ± 1.20
BB-15 þ0 60.00 13.00 3.00 5.35 ± 0.20 60.02 ± 1.24
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 6 8e2 7 8272For BoxeBehnken analyses, the regression equation de-
scribes the effects of the variables on the responses in terms of
linear, interactive and quadratic. The equation followed as:
Y ¼ b0 þ b1X1 þ b2X2 þ b3X3 þ b12X1X2 þ b13X1X3 þ b23X2X3
þ b11X21 þ b22X22 þ b33X23
where, b0 is intercepted, and Y is the measured response
associated with the factors (X1, X2 and X3), their interactions







values related to the regression coefficients indicated the
significance of the factors on the response. ANOVA and the
coefficient of determination (R2) were also applied to deter-
mine the suitability of the model [12].3. Results and discussion
3.1. Risk assessment
Risk assessment aims to obtain all the potential high impact
factors which will be subjected to a DOE study to establish a
product or process DS. Just like outlined in the ICH Q9 docu-
ment, risk identification and risk analysis are two basic
components of risk assessment [13]. The first step in the risk
assessment was to systematically gather up all the possible
factors that could influence product quality. Basing on the
literature data, previous study experiences [14,15] and pre-
formulation data, fish-bone diagrams [16] was applied to
organize hierarchically these factors (see Fig. 2). The RPN
scores using FMEA methodology was depicted Fig. 3. To
initiate the FMEA, we broke the failuremodes down into those
coming from the formulation, process, people, environment,
and equipment inputs. Except the formulation and process,
other factors leading to the variability in product quality were
considered to be lower risk since all the development work
was conducted under the conditions which were usually fixed
by preliminary experiments and/or prior knowledge. In addi-
tion, variables that could affect in vivo performance have
generally been scored high.Eight high-risk factors identified in a risk analysis study
have potential impact on Y1 and Y2 which were taken as in-
dexes evaluating CQAs. These independent factors included:
TEC percentage (X1, compared to polymer), GMS percentage
(X2, compared to polymer), spray rate (X3), atomizing pressure
(X4), batch size (X5), coating aqueous dispersion solid content
(X6, amount of all the solid compared to the amount of the
coating aqueous dispersion), coating weight gain (X7) and
curing time (X8), these eight factors would be used for further
screening study to obtain the significant factors influencing
selected CQAs by PlacketteBurman design.3.2. Influence of various factors on Y1 and Y2 by
PlacketteBurman screening DOE
The goal of this study was to identify the most significant
factors affecting the CQAs using PlacketteBurman design.
PlacketteBurman design can estimate the significance of the
main factor from large numbers of factors with very high ef-
ficiency and accuracy [17], thus assuring to quickly reduce the
number of high-risk factors needed to be studied in the next
step. An eight factors-two levels-12 runs PlacketteBurman
screening study was performed using Minitab statistical
experiment design software and the responses were Y1 and
Y2.
As learned from Table 1, Y1 and Y2 varied from 3.37% (PB-8)
to 12.47% (PB-6), and from 72.47% (PB-8) to 90.11% (PB-6),
respectively, for the various factor combinations. Fig. 4 indi-
cated that among all of the factors, coating weight gain, TEC
percentage and GMS percentage (P < 0.05) strikingly influ-
enced acid resistance, while cumulative drug release was
significantly impacted by coating weight gain and GMS per-
centage (P < 0.05). As recorded in Table 3, the relative strength
of each factor influencing CQAs was further in detail depicted
by the “Effect” value. A positive value indicates an effect that
helps to enhance the response value; conversely a negative
sign value represents an inverse relationship between the
response and the factor. The higher the absolute value the
greater the effect of that factor on the responses. Lower Y1 and
Fig. 2 e An Fish-bone diagram illustrating factors that may have impact on acid resistance and cumulative drug release.
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that decreased TEC/GMS percentage and increased coating
weight gain would contribute to lower Y1. While both
increasing the GMS and decreasing the coating weight gain
would resulted in the increase of Y2. Eudragit L30D-55 was
enteric-coated material, which dissolves merely in pH 5.5 or
abovemedium. The larger the coatingweight gains the thicker
of coating film. An attempt to decrease the coating film
excessively would result in discontinuous coating film so that
leading to too much drug release in the gastric region. InFig. 3 e Pareto chart showing RPN scores for the operating para
scores higher than the threshold (RPN ¼ 60) were considered focontrary, exorbitant thick film might handicap drug releasing
from formulation and Y2 turned out to be too low. TEC was
plasticizer which can decrease the film forming temperature
to favor coating. Besides, TEC was also hydrophilic material,
which was easily dissolved in water thus playing a pore-
forming agent role in the enteric-coated film. For this
reason, too high levels of TEC will result in too much drug
release in gastric environment, while the low value TEC can't
decrease the film forming temperature during coating process
in efficiency. GMS was an antisticking agent, which canmeters for ECPs coating process. Parameters that had RPN
r further experimentation.
Fig. 4 e Standard Pareto charts showing the effects of independent variables on acid resistance and on cumulative drug
release.
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avoid the adhesion among pellets and it also benefits for
coating process. As emulsifier Tween-80 was always accom-
pany with GMS, which was 40% of the amount of GMS. It is
well known that Tween-80 is well hydrophilic surfactant,
when GMS was in the high content meaning Tween-80 was
also in the high levels, for the same reason like TEC which
would result in poor product quality. Too low GMS content
could not decrease the viscosity of coating aqueous disper-
sion, but would lead to the failure of the adhesion among
pellets during development and coating. A good correlation
was obtained between the observed and predicted values as
indicated by the R2 value of 0.9510 and 0.9701for Y1 and Y2.
Basing on the result of the screening study, it is concluded
that the responses were impacted significantly by coating
weight gain, TEC percentage and GMS percentage. These three
parameters were further examined for their interactions and
their effects on product quality attributes via the
BoxeBehnken DOE. From the Coef. of Table 3, it inferred that
spray rate has an inverse impact on the Y1 and Y2, and which
was at a low value favoring to improve product quality; all of
the residual factors of atomizing pressure, batch size, coating
aqueous dispersion solid content and curing time were found
to be less significant and hence kept at 0.02 MPa, 5 g, 20%, and
15 min, respectively, considering cost and time saving in the
next phase.Table 3 e Estimated effects and coefficients for acid resistance
Term Effect Coef
Y1 Y2 Y1 Y2
Constant 8.602 81.022
TEC 2.863 2.847 1.432 1.423
GMS 2.677 3.407 1.338 1.703
Spray rate 1.29 0.437 0.645 0.218
Atomizing pressure 0.507 1.063 0.253 0.532
Batch size 0.97 0.74 0.485 0.37
Solid content 0.423 2.03 0.212 1.015
Coating weight gain 3.693 7.933 1.847 3.967
Curing time 0.397 0.567 0.198 0.283
*Means P-value is less than the a priori value of 0.05 and is statistically s3.3. The responses surface for both Y1 and Y2 were
obtained by BoxeBehnken DOE
This study aimed at understanding the effects and in-
teractions between coating weight gain, TEC percentage and
GMS percentage on Y1 and Y2. The levels used for selected
parameters and the experimental results are listed in Table 2.
As shown in Table 2, Y1 and Y2 varied from 4.51% to 13.12%
and from 56.17% to 100.13%, respectively. Table 4 illustrated
the statistical analysis results using Design Expert software;
the values of the regression coefficients (coded) of the vari-
ables are associated with the influence on the CQAs. The
largest part of the absolute values for the coefficients (coded)
meant the variables had the most potential effect on the
response. Analysis of variance (ANOVA) was performed to
evaluate the model significance. A model will be considered
statistically significant if the P-value represented by “Prob > F”
is 0.05 or less. F-ratio is the “mean square between” divided by
the ‘‘mean square within’’. The low value of the F-ratio's
means more errors in the model. The adequacy of the devel-
oped models were estimated by “lack of fit”, R2, adjust R2 [R2
(adj)] and predicted R2 [R2 (pred)]. The “lack of fit” estimates
the error variance independently of the model. A significant
‘‘Lack of Fit’’ (P > 0.05) indicates that the variability measured
by the replicates does not explain the gap between predicted
and experimental data points. The R2 value is the maximum(Y1) and for cumulative drug release (Y2) (coded units).
Std Err Coef T P
Y1 Y2 Y1 Y2 Y1 Y2
0.3719 0.4784 23.13 169.37 0 0
0.3719 0.4784 3.85 2.98 0.031* 0.059
0.3719 0.4784 3.6 3.56 0.037* 0.038*
0.3719 0.4784 1.73 0.46 0.181 0.679
0.3719 0.4784 0.68 1.11 0.545 0.347
0.3719 0.4784 1.3 0.77 0.283 0.496
0.3719 0.4784 0.57 2.12 0.609 0.124
0.3719 0.4784 4.96 8.29 0.016* 0.004*
0.3719 0.4784 0.53 0.59 0.631 0.595
ignificant.





Coefficient (uncoded) F-ratio P
Y1 Y2 Y1 Y2 Y1 Y2 Y1 Y2 Y1 Y2
Constant 7.98 83.37 0.14 0.82 14.57395 106.71152 202.57 153.64 ＜0.0001* ＜0.0001*
X7 3.36 17.35 0.084 0.5 0.31649 0.77402 1600.61 1197.7 ＜0.0001* ＜0.0001*
X1 0.94 5.77 0.084 0.5 0.20394 1.08651 124.52 132.37 0.0001* ＜0.0001*
X2 0.47 1.88 0.084 0.5 0.50696 0.4776 31.13 14.08 0.0025* 0.0133*
X7*X1 0.075 2.26 0.12 0.71 1.11E03 0.033481 0.4 10.16 0.5556 0.0243*
X7*X2 0.17 1.17 0.12 0.71 2.13E03 0.014889 1.99 2.74 0.2177 0.1591
X1*X2 0.25 0.02 0.12 0.71 0.02381 1.90E03 4.43 7.96E04 0.0893 0.9786
X27 0.94 3.57 0.12 0.74 1.85E03 7.05E03 57.42 23.42 0.0006* 0.0047*
X21 0.03 0.61 0.12 0.74 3.38E-03 0.067917 0.06 0.69 0.8155 0.4454
X22 0.24 0.45 0.12 0.74 0.019354 0.037041 3.68 0.38 0.1133 0.5655
*Means P-value is less than the a priori value of 0.05 and is statistically significant.
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using only the variables in it, which is an indication of how
well the model fits the experimental data, and the closer the
value is to 1, the better the model is. The R2 (adj) is a modified
form of R2 considering the number of terms used within the
model and the R2 (pred) is an estimation of howwell themodel
predicts a response value. Table 4 demonstrated the suggested
most suitable model were quadratic for both responses of Y1
and Y2.
In Table 4, it was observed that Y1was significantly affected
by coating weight gain, TEC percentage and GMS percentage
(P < 0.05). Analysis of variance (ANOVA) in Table 5 manifested
that the model was statistically significant in its prediction of
Y1, as depicted by Prob > F of 0.0032, F-ratio of 20.02 and the
Prob> F for “lack of fit”of 0.3882. ThemodelwasgoodwithR2 of
0.9973, and can well depict independent factors on the
response (Y1) with good the R
2 (adj) and the R2 (pred). Table 4
implied no coating weight gain-TEC percentage-GMS per-
centage interaction on Y1 for all of the P-value > 0.05.
The three studied factors were also investigated inY2. As
learned from regression analysis, coating weight gain was
inversely correlated with increasing Y2 (P < 0.05) (Table 4). The
increase in TEC and GMS percentage was also observed to
significantly increase Y2 (P < 0.05). There was a striking
interaction between the coating weight gain and the TEC
percentage with respect to an increase in the Y2 (P < 0.05).
ANOVA statistics elucidated that a “Prob > F” of 0.0205, F-ratio
of 8.57 and the Prob> F for “lack of fit” of 0.1639, indicating that
the factors in the model were significant. In addition, the
model was speculated to well predict the response with R2, R2
(adj) and the R2 (pred) were 0.9964, 0.9899 and 0.9479,
respectively.
Counter and response surface plots were also analyzed to
visualize the effects of the parameters and their interactionsTable 5 e Summary of ANOVA and lack of fit for testing mode
Source ANOVA para
DF SS MS Prob > F F-ra
Q2h 3 3.39 1.13 0.0032 20.0
Qcumulative 3 51.66 17.22 0.0205 8.5on the responses. Fig. 5 showed the effects of coating weight
gain, TEC percentage and GMS percentage on Y1 and Y2.
3.4. Establishment and evaluation of the DS
DS was defined by the ICH Q8 as “the multidimensional
combination and interaction of input variables (material at-
tributes) and process parameters that have been demon-
strated to provide assurance of quality. Working within the
design space is not considered as a change; however the
movement out of the design space is considered a change and
would normally initiate a regulatory post approval change
process. Design space is proposed by the applicant and is
subject to the regulatory assessment and approval” [5]. The DS
makes QbD a reality and the wider the DS, the more robust
and flexible the process is to accommodate variations. In this
study, RSM in conjunction with optimization was applied to
establish DS.
The quadratic response surface of CQAs as a function of
selected variables was given in Fig. 5. The objective of opti-
mization is to optimize input variables range for meeting a
goal. A vital step of optimization is to achieve appropriate
response functions for both dependences and independences.
In Design Expert, the desirability response values were set
Y1  10% and Y2  80%. When GMS was at low and high limits
set in experiment, Fig. 6A and B showed the proposed DS,
comprised of the yellow overlap region of ranges for the two
CQAs. As depicted in Fig. 6C. the overlay part of the yellow
region in Fig. 6Awith B satisfied both Y1 10% andY2 80%, in
which GMSwas from 3% to 10%. However, coating weight gain
and TEC percentage were variables and it was difficult to
determine the exact value in real operation during develop-
ment. Hereby, In order to determine the range of TEC per-
centage and coating weight gain and to achieve the mostl.
meters Prob > F
tio R2 R2 (adj) R2 (pred) (Lack of fit)
2 0.9973 0.9923 0.9667 0.3882
7 0.9964 0.9899 0.9479 0.1639
Fig. 5 e Response surface (3D) plot of the effects of variables on the acid resistance and on the cumulative drug release of
prepared ECPs. (A) coating weight gain/GMS and (B) coating weight gain/TEC were on the acid resistance; (C) coating weight
gain/GMS and (D) coating weight gain/TEC were on cumulative drug release.
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applied here to develop the relationship between coating
weight gain and TEC percentage. Specifically, a biggest
inscribed parallelogram was plotted in the orange overlay
region shown in Fig. 6D, whose abscissa of X7 and ordinate of
X1, the four coordinates were (23%, 10%), (33%, 10%), (36.5%,
16%), and (46.5%, 16%), respectively. It was easy to obtain the
exact value of X1 and X7 inside the parallelogram with math
knowledge. The DS was established which was delineated in
the orange region in Fig. 6D, the range of the independent was,
GMS percentage of 3%e10%, coating weight gain and TEC
percentage of the point inside the orange parallelogram re-
gion. Known from the variables range of DS, the range of TEC
percentage and GMS percentage were thoroughly same with
the BoxeBehnken DOE. Based on the preformulation experi-
ence, levels of TEC and GMS must be in the certain range to
ensure that the production was performed favorably. Such
results don't mean that the fixed range of variables was too
small, but illustrated that the available operation range was
wide in manufacture ensuring product quality.
3.5. Determination of control strategy of the prepared
NAP-ECPs
For ensuring a product of required quality of robustness and
consistency during producing, ICH Q10 defines the control
strategy as “a planned set of controls, derived from the un-
derstanding of current product and process that assuresprocess performance and product quality” [18]. The normal
operating ranges is CS which is defined as the upper and/or
lower limits for the critical material attributes and CPP. In the
CS, the parameters were routinely controlled during produc-
tion in order to assure the reproducibility [1]. The acceptable
range of bothmaterial attributes and process parameterswere
determined basing on the knowledge space from screening
design and DS, the detail information was following as Fig. 7.
3.6. Confirmation tests
To evaluate the accuracy and robustness of the obtained
model, a confirmation test was carried out with low, medium
and high value of all the eight factors within CS. The model
confirmation experiments design and results were shown in
Table 6. The results showed that the predicted and observed
responses values of the formulations with the different vari-
ables combinations were nearly similar. A good agreement
was obtained between themodel prediction and experimental
observation. Thus, the validity of the model was established
and the formulation variables and process parameters were
robust within the control space.
In QbD, robustness estimation is moved into method
optimization for the definition of DS to ensure the CQAs
values which were deduced from any working inside the DS
are acceptable [19]. Once the DS is established, the validation
becomes an exercise to demonstrate that the process will
deliver a product of acceptable quality when operating within
Fig. 7 e The control space of the prepared NAP-ECPs.
Fig. 6 e Design space of prepared ECPs comprised of the overlap region of ranges for the three CQAs using GMS percentage of
(A) 3% and (B) 10%; (C) the theory region and (D) the operating region.
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Table 6 eModel confirmation experiments design table. X1: TEC percentage (%w/w); X2: GMS percentage (%w/w); X3: spray
rate (ml/min); X4: atomizing pressure (MPa); X5: batch size (g); X6: coating aqueous dispersion solid content (%w/w); X7:
coating weight gain (%w/w); X8: curing time (min). The response acid resistance (Y1, %) and drug cumulative release (Y2, %)
were reported as mean ± SD for experimental value.
Level X1 X2 X3 X4 X5 X6 X7 X8 Y1 Y2
Predicted Experimental Predicted Experimental
Low 10 3 0.15 0.02 5 15 23 15 9.70 9.62 ± 0.14 88.68 89.36 ± 1.36
Medium 13 6.5 0.2 0.03 6.5 20 34.75 67.5 8.34 8.77 ± 9.15 85.44 84.64 ± 1.28
High 16 10 0.25 0.04 8 25 46.5 120 8.64 8.66 ± 0.17 85.93 85.05 ± 1.34
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lines on how to estimate the DS level [19] and no new concept
exists to implement a control strategy in the pharmaceutical
industry [21]. Within our approach, basing on the initial risk
assessment and DS, a CS created with all the eight factors was
involved. The confirmation tests illustrated that both the un-
important factors had little effect on the selected CQAs and
the robustness of the model.4. Conclusion
This current case study demonstrated how QbD approach can
be applied toward the development of the ECPs preparation.
Fish-bone paragraph and FMEA analysis favors to identify
critical formulation and process parameters that affect ECPs
product quality. And next, the PlacketteBurman and
BoxeBehnken design were used for screening the significant
factors and optimizing the variables range, respectively. The
final aim of this approach is to achieve a process model of the
ECPs preparation, thus a DS can be established based on it,
and a CS could be further obtained. Confirmation tests were
carried out at three levels of low, medium and high of the
variables and the results manifested that the prediction and
experimental observation were in a good agreement, which
confirmed the accuracy and robustness of the model.
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